Covington-based Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, discussed data from 17 patients enrolled in the Phase Ia portion of its ongoing Phase I Safety Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting Poster Session, held in Chicago June 1-5.
In the poster presentation entitled, “First-in-class Phase Ia Study of BXQ-350 for Solid Tumors and Gliomas”, the preliminary data showed:
*9 patients with Glioblastoma Multiforme (GBM); 8 patients with other solid tumors
*Patients had a median 7 prior systemic therapies
*No Dose Limiting Toxicities (DLTs)
*No treatment –related serious adverse events (SAEs)
*Most common treatment-related moderate AEs were transient fatigue
*Best response in 7 patients completing to day 113:
– 1 Partial Response (appendiceal carcinoma)
– Stable Disease (improved day 113 RANO/RECIST)
*1 High Grade Glioma Stable Disease >19+ months
“Bexion’s team was excited to share our Phase Ia data at the ASCO conference,” stated Dr. Ray Takigiku, founder and CEO. “With this promising data indicating the potential for a tumor agnostic approach, Bexion is now enrolling patients with solid tumors and gliomas in Phase 1b, and we are initiating efforts to towards a Phase 1 trial in pediatrics and combination Phase 2 studies in adults.”
BXQ-350 is a unique formulation of a synthetically produced, human lysosomal protein, Saposin C (sphingolipid activator protein, or SapC), and the phospholipid dioleoylphosphatidylserine (DOPS).
Bexion Pharmaceuticals is a privately-held biotech company focused on the development and commercialization of innovative cures for cancer. Bexion’s first-in-class biologic, BXQ-350, has demonstrated selective tumor targeting with the potential for clinical efficacy in a broad range of cancers.
In 2013 the NCI awarded Bexion a prestigious “Bridge Award” of $3MM to support testing of BXQ-350 in the clinic. In February 2015, the FDA granted Bexion Orphan Drug status for Saposin C, the active ingredient in its proprietary drug BXQ-350, for the potential treatment of glioblastoma multiforme (GBM), a type of brain cancer.
In June 2015, Bexion won a Tibbett’s Award by the Small Business Administration for exemplifying the very best in innovation. Currently Bexion is in a Series B Fund Raise. For more information, click here.
Bexion Pharmaceuticals